HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir

RegulatoryrejectedlenacapavirNegative

AI Analysis

Summary

NICE issued an initial negative recommendation against NHS coverage of Gilead's twice-yearly injectable lenacapavir for HIV prevention, disappointing HIV charities. The recommendation has not been finalized.

Outcome Details

NICE initial recommendation against NHS coverage for twice-yearly injectable lenacapavir

Importance:6/10

Sentiment:

-0.80

NICENHSregulatory decisionHIV preventionPrEPcoverage denial

Related Companies

$GILD

Read the original article

Published by Pharmaceutical Technology on September 11, 2026 1:10 PM

Read Original